Skip to main content
. Author manuscript; available in PMC: 2021 Mar 1.
Published in final edited form as: Thromb Res. 2020 Jan 15;187:131–138. doi: 10.1016/j.thromres.2020.01.014

Figure 4. Levels of Anti-FXa and thrombin following enoxaparin treatment of PE vs no PE patients.

Figure 4.

Anti-FXa levels (A) and changes in peak thrombin (B) were measured in plasma from patients who did (white bar) or did not develop a PE (black bar) following treatment with enoxaparin in the presence or absence of FFP or AT supplementation. Data are presented as means with standard deviation. * denotes p<0.05 comparing “PE” and “No PE” patients after two-way ANOVA analysis with Sidak correction.